Welcome to our dedicated page for Solid Bioscience SEC filings (Ticker: SLDB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Solid Biosciences Inc. (SLDB) files reports and disclosures with the U.S. Securities and Exchange Commission as a Nasdaq-listed issuer. These SEC filings provide detailed information on the company’s clinical programs, financial condition, risk factors and material corporate events related to its development of precision genetic medicines for rare neuromuscular and cardiac diseases.
Among the documents available, Form 10-K annual reports and Form 10-Q quarterly reports typically discuss Solid Biosciences’ gene therapy pipeline, including SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich’s ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia and SGT-601 for TNNT2-mediated dilated cardiomyopathy, along with its AAV-SLB101 capsid platform and broader development activities. These filings outline the company’s business description, research and development focus and key risks.
Form 8-K current reports, such as the filing describing interim data from the INSPIRE DUCHENNE Phase 1/2 trial of SGT-003, provide updates on material events, including clinical data readouts, regulatory developments, corporate presentations and other significant announcements. Investors can also review information on equity awards and stock plans, as referenced in company communications about inducement grants made under Nasdaq Listing Rule 5635(c)(4).
This SEC filings page offers real-time access to Solid Biosciences’ submissions from the EDGAR system, along with AI-powered summaries that highlight key points from lengthy documents. Users can quickly identify disclosures on clinical trial progress, gene therapy strategy, regulatory interactions and other factors that may be important when evaluating SLDB.
Solid Biosciences insider David T. Howton filed a Rule 144 notice to sell 18,894 shares of common stock through E*TRADE Financial on NASDAQ, with an aggregate market value of $121,708.27.
These shares were acquired on 02/04/2026 via settlement of vested restricted stock units as compensation. Over the prior three months, Howton sold 4,932 shares for $25,202.52 on 12/03/2025 and 37,771 shares for $243,128.15 on 02/02/2026.
An insider of the issuer filed a notice to sell 12,348 shares of common stock under Rule 144. These shares are to be sold through ETRADE Financial Corporation on NASDAQ, with an aggregate market value of 79,541.32 and 82,569,192 shares of the same class outstanding.
The shares were acquired on 02/04/2026 through settlement of vested restricted stock units as compensation from the issuer. The same person previously sold 4,483 shares for 22,908.13 on 12/03/2025 and 26,535 shares for 170,803.14 on 02/02/2026.
Solid Biosciences shareholder Brooks Gabriel filed a Rule 144 notice to sell 12,616 shares of common stock through E*TRADE on NASDAQ, with an aggregate market value of $81,267.65. The filing shows 82,569,192 shares of common stock outstanding.
The 12,616 shares were acquired the same day via settlement of vested restricted stock units as compensation from the issuer. The notice also reports that Gabriel sold 28,335 shares of common stock in a prior transaction on 02/02/2026, generating gross proceeds of $182,389.56.
Solid Biosciences CFO & Treasurer Kevin Tan reported multiple equity transactions. On January 29, 2026, 56,646 performance stock units converted one-for-one into common stock, increasing his directly held common shares to 102,746. That same day he received an employee stock option for 187,000 shares vesting over four years and a new grant of 93,500 restricted stock units, also vesting over four years.
On January 31, 2026, 33,075 restricted stock units from a prior 2025 grant vested and converted into common stock, lifting his direct holdings to 135,821 shares. On February 2, 2026, he sold 26,837 shares at a weighted average price of $6.4369 solely to cover withholding taxes under a pre-arranged automatic sell-to-cover instruction, leaving 108,984 common shares held directly.
Solid Biosciences Inc.’s President and CEO Alexander Cumbo reported multiple equity compensation events and a tax-related share sale. On January 29, 2026, 169,401 performance stock units vested into common shares, he received an option grant for 509,850 shares at $6.60, and was granted 254,900 RSUs.
On January 31, 2026, 100,400 RSUs from a prior grant vested into common stock. On February 2, 2026, Cumbo sold 80,258 shares at a weighted average price of $6.4369 to cover withholding taxes under an automatic sell-to-cover instruction, leaving him with 270,931 directly held common shares plus unvested RSUs and options.
Solid Biosciences Inc. Chief Regulatory Officer Jessie Hanrahan reported equity vesting, new grants, and a tax-related share sale. On January 29, 2026, 54,925 performance stock units converted into common stock and 190,000 employee stock options plus 95,000 restricted stock units were granted.
On January 31, 2026, 27,625 restricted stock units vested into common shares. On February 2, 2026, 26,535 common shares were sold at a weighted average price of $6.4369 to cover withholding taxes under a pre-established automatic sell-to-cover instruction, leaving 82,675 common shares held directly.
Solid Biosciences Inc. Chief Medical Officer Gabriel Brooks reported multiple equity compensation events and a related stock sale. On January 29, 2026, 58,847 performance stock units vested into common stock after a performance milestone was certified as achieved, increasing his holdings before later transactions.
That same day, he received an option to buy 207,450 shares at an exercise price of $6.60 per share, vesting over four years, and 103,750 restricted stock units that also vest over four years in 25% annual installments. On January 31, 2026, 28,225 restricted stock units from a 2025 grant vested into common stock.
On February 2, 2026, Brooks sold 28,335 shares of common stock at a weighted average price of $6.4369 per share to cover withholding taxes after PSU vesting under a pre-arranged automatic sell-to-cover instruction. Following these transactions, he directly held 96,708 shares of Solid Biosciences common stock.
Solid Biosciences’ Chief Operating Officer David Howton reported multiple equity compensation events and a related share sale. On January 29, 2026, 79,341 performance stock units vested and converted into common stock, and he received 105,100 new restricted stock units plus an option for 210,200 shares at an exercise price of $6.60 per share, all vesting over four years.
On January 31, 2026, an additional 42,275 restricted stock units vested and converted into common stock. On February 2, 2026, he sold 37,771 shares of common stock at a weighted average price of $6.4369 solely to cover withholding taxes under a pre-established automatic sell-to-cover instruction, and continued to hold 116,753 shares directly afterward.
Solid Biosciences Chief Technology Officer Paul Herzich reported several equity award events and a related share sale. On January 29, 2026, 54,925 performance stock units vested and converted one-for-one into common stock after a performance milestone was certified as achieved.
On the same date, he received an option to buy 170,000 shares at an exercise price of $6.60 per share, vesting over four years, and was granted 85,000 restricted stock units, also vesting over four years. On January 31, 2026, 24,675 RSUs from a 2025 grant vested and converted into common shares.
On February 2, 2026, Herzich sold 26,250 common shares at a weighted average price of $6.4369 per share to cover withholding taxes after PSU vesting, under a durable automatic sell-to-cover instruction, and not as a discretionary trade. After these transactions, he directly owned 79,972 common shares.
Solid Biosciences director Ilan Ganot reported several equity compensation events and updated holdings. On January 29, 2026, an entity associated with his wife received an employee stock option for 70,900 shares of common stock at an exercise price of $6.6 per share, vesting over four years. On the same date, his wife was also granted 35,450 restricted stock units (RSUs), which vest in four equal annual installments.
On January 31, 2026, 15,000 RSUs associated with his wife were settled into 15,000 shares of common stock, increasing her indirect common stock holdings to 32,476 shares and RSU holdings to 45,000 units. Separately, Ganot directly and jointly holds 99,297 shares of common stock and an additional 19,394 shares are held in the Ilan Ganot 2017 Irrevocable Trust.